163 related articles for article (PubMed ID: 37585633)
1. Targeting IDH in Low-Grade Glioma.
Claus EB; Verhaak RGW
N Engl J Med; 2023 Aug; 389(7):655-659. PubMed ID: 37585633
[No Abstract] [Full Text] [Related]
2. Headway against Brain Tumors with Molecular Targeting of IDH-Mutant Gliomas.
Schiff D
N Engl J Med; 2023 Aug; 389(7):653-654. PubMed ID: 37585632
[No Abstract] [Full Text] [Related]
3. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.
Kitagawa Y; Kobayashi A; Cahill DP; Wakimoto H; Tanaka S
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189102. PubMed ID: 38653436
[TBL] [Abstract][Full Text] [Related]
4. Large-Scale Drug Screening in Patient-Derived IDH
Dao Trong P; Jungwirth G; Yu T; Pusch S; Unterberg A; Herold-Mende C; Warta R
Cells; 2020 Jun; 9(6):. PubMed ID: 32503220
[TBL] [Abstract][Full Text] [Related]
5. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.
Sun H; Yin L; Li S; Han S; Song G; Liu N; Yan C
J Neurooncol; 2013 Jun; 113(2):277-84. PubMed ID: 23504258
[TBL] [Abstract][Full Text] [Related]
7. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
8. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
[TBL] [Abstract][Full Text] [Related]
9. Deconvolution and network analysis of IDH-mutant lower grade glioma predict recurrence and indicate therapeutic targets.
Li G; Jiang Y; Lyu X; Cai Y; Zhang M; Wang Z; Li G; Qiao Q
Epigenomics; 2019 Aug; 11(11):1323-1333. PubMed ID: 31272213
[No Abstract] [Full Text] [Related]
10. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
12. On high-risk, low-grade glioma: What distinguishes high from low?
Geurts M; van den Bent MJ
Cancer; 2019 Jan; 125(2):174-176. PubMed ID: 30512190
[TBL] [Abstract][Full Text] [Related]
13. IDH-mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature.
Chang EK; Smith-Cohn MA; Tamrazi B; Ji J; Krieger M; Holdhoff M; Eberhart CG; Margol AS; Cotter JA
Brain Pathol; 2021 Jul; 31(4):e12959. PubMed ID: 33960568
[TBL] [Abstract][Full Text] [Related]
14. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
15. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
16. Glioma Response to IDH Inhibition: Real-World Experience.
Lukas RV; Horbinski C
Clin Cancer Res; 2023 Dec; 29(23):4709-4710. PubMed ID: 37738033
[TBL] [Abstract][Full Text] [Related]
17. A new era for glioma therapy - targeting mutant IDH.
Reardon DA; Cahill DP
Nat Rev Clin Oncol; 2023 Nov; 20(11):737-738. PubMed ID: 37460634
[No Abstract] [Full Text] [Related]
18. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
19. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
[TBL] [Abstract][Full Text] [Related]
20. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
